![CME Programme CSHK mw_menu_data_5564_56eb2b174e5e3.jpg](https://cshk.org/site/CSHK/upload/mw_menu_data/file/mw_menu_data_5564_56eb2b174e5e3.jpg)
CME Programme
-
Non-Regular Activities
Real-world Insights: Sacituzumab Govitecan in HER2- mBCDate: 23/04/2024 Enquiries: Hong Kong Breast Oncology Group CME Points Awarded: 2 points
CME Programme
Date: | 23/04/2024 |
Enquiries: | Hong Kong Breast Oncology Group |
CME Points Awarded: | 2 points |